A related allosteric Akt inhibitor, and the most clinically promising [52] compound, MK-2206 significantly reduces Ser473 phosphorylation after 10 h in mouse models with patient-derived xenografts of endometrial tumors [53]. Here, AKT1 is linked to endometrium neoplasm.